原发性胆汁性胆管炎患者血清MicroRNA的表达谱分析
Analysis of Serum MicroRNA Expression Profile in Patients with Primary Biliary Cholangitis
DOI: 10.12677/ACM.2022.123295, PDF,    科研立项经费支持
作者: 徐田田, 王 战, 李文帅, 刘明军*:青岛大学附属医院,山东 青岛
关键词: 原发性胆汁性胆管炎miRNAs高通量测序Primary Biliary Cholangitis miRNAs High-Throughput Sequencing
摘要: 目的:研究原发性胆汁性胆管炎(Primary biliary cholangitis, PBC)患者血清中microRNAs的差异表达与临床价值。方法:首先,采用高通量测序筛选PBC组和正常对照组中差异表达的miRNAs,其次,采用实时荧光定量PCR (qRT-PCR)对差异表达的miRNAs在扩大样本中进行验证。最后,预测miRNAs的靶基因。结果:高通量测序筛选出94条miRNAs,其中,60条miRNAs表达上调,34条miRNAs表达下调。经过qRT-PCR验证发现miR-410-3p在PBC组中的表达水平明显高于正常对照组,与测序结果一致。靶基因预测结果提示,miR-410-3p的相关靶基因与T细胞或B细胞的分化、活化、增殖、稳态相关。结论:PBC患者血清中存在差异表达的miRNAs,miR-410-3p对PBC的诊断有一定的参考价值。
Abstract: Objective: To investigate the differential expression and clinical value of microRNAs in the serum of patients with primary biliary cholangitis (PBC). Methods: First, high-throughput sequencing was used to screen differentially expressed miRNAs in PBC group and normal control group. Second, qRT-PCR was used to verify the differentially expressed miRNAs in expanded samples. Finally, computer analysis was conducted to predict target genes. Results: By high-throughput sequencing, we found 94 miRNAs were differentially expressed in PBC patients compared to the normal controls. The analysis identified 60 up-regulated miRNAs (>2.0-fold) and 34 down-regulated miRNAs (<0.5-fold). qRT-PCR verified that the expression of miR-410-3p was significantly up-regulated in PBC patients compared with the normal controls, which was consistent with the deep sequencing results. The prediction results of target genes suggested that the related target genes of miR-410-3p were involved in the differentiation, activation, proliferation and homeostasis of T cells or B cells. Conclusion: There are differentially expressed miRNAs in the serum of PBC patients. miR-410-3p has certain reference value for the diagnosis of PBC.
文章引用:徐田田, 王战, 李文帅, 刘明军. 原发性胆汁性胆管炎患者血清MicroRNA的表达谱分析[J]. 临床医学进展, 2022, 12(3): 2056-2063. https://doi.org/10.12677/ACM.2022.123295

参考文献

[1] Wang, X., Wen, X., Zhou, J., et al. (2017) MicroRNA-223 and MicroRNA-21 in Peripheral Blood B Cells Associated with Progression of Primary Biliary Cholangitis Patients. PLoS ONE, 12, e0184292. [Google Scholar] [CrossRef] [PubMed]
[2] Song, Y., Yang, H., Jiang, K., Wang, B.M. and Lin, R. (2018) MiR-181a Regulates Th17 Cells Distribution via Up-Regulated BCL-2 in Primary Biliary Cholangitis. International Immunopharmacology, 64, 386-393. [Google Scholar] [CrossRef] [PubMed]
[3] Joshita, S., Umemura, T., Tanaka, E. and Ota, M. (2018) Genetics and Epigenetics in the Pathogenesis of Primary Biliary Cholangitis. Clinical Journal of Gastroenterology, 11, 11-18. [Google Scholar] [CrossRef] [PubMed]
[4] Toh, B.H. (2017) Diagnostic Autoantibodies for Autoimmune Liver Diseases. Clinical & Translational Immunology, 6, e139. [Google Scholar] [CrossRef] [PubMed]
[5] Pan, H., Dai, H., Wang, L., et al. (2020) MicroRNA-410-3p Modulates Chondrocyte Apoptosis and Inflammation by Targeting High Mobility Group Box 1 (HMGB1) in an Osteoarthritis Mouse Model. BMC Musculoskeletal Disorders, 21, Article No. 486. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, L., Wu, H., Zhao, M., Chang, C. and Lu, Q. (2020) Clinical Significance of miRNAs in Autoimmunity. Journal of Autoimmunity, 109, Article ID: 102438. [Google Scholar] [CrossRef] [PubMed]
[7] 潘腾莉, 孙莉, 周兴蓓, 陈丽, 於学军, 谭友文. 血清microRNA表达谱对原发性胆汁性肝硬化的诊断价值[J]. 江苏大学学报, 2014, 24(3): 230-234.
[8] Katsumi, T., Ninomiya, M., Nishina, T., et al. (2016) MiR-139-5p Is Associated with Inflammatory Regulation through c-FOS Suppression, and Contributes to the Progression of Primary Biliary Cholangitis. Laboratory Investigation, 96, 1165-1177. [Google Scholar] [CrossRef] [PubMed]
[9] Rodrigues, P.M., Perugorria, M.J., Santos-Laso, A., et al. (2018) Pri-mary Biliary Cholangitis: A Tale of Epigenetically-Induced Secretory Failure? Journal of Hepatology, 69, 1371-1383. [Google Scholar] [CrossRef] [PubMed]
[10] 梁冬雨, 高得勇, 娄晓丽, 侯彦强. 原发性胆汁性肝硬化血浆microRNA表达谱的初步分析[J]. 中华检验医学杂志, 2014, 37(8): 608-612.
[11] Jadideslam, G., Ansarin, K., Sakhinia, E., et al. (2018) The MicroRNA-326: Autoimmune Diseases, Diagnostic Biomarker, and Therapeutic Target. Journal of Cellular Physiology, 233, 9209-9222. [Google Scholar] [CrossRef] [PubMed]
[12] Xia, Y., Tao, J.H., Fang, X., et al. (2018) MicroRNA-326 Upregulates B Cell Activity and Autoantibody Production in Lupus Disease of MRL/lpr Mice. Molecular Therapy—Nucleic Acids, 11, 284-291. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, H., Feng, L., Zheng, Y., et al. (2020) LINC00680 Promotes the Progression of Non-Small Cell Lung Cancer and Functions as a Sponge of miR-410-3p to Enhance HMGB1 Expression. OncoTargets and Therapy, 13, 8183-8196. [Google Scholar] [CrossRef
[14] Ma, Z.H., Shi, P.D. and Wan, B.S. (2021) MiR-410-3p Activates the NF-κB Pathway by Targeting ZCCHC10 to Promote Migration, Invasion and EMT of Colorectal Cancer. Cytokine, 140, Article ID: 155433. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, Y., Hou, L., Yuan, X., et al. (2020) LncRNA NEAT1 Targets Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via the miR-410-3p/YY1 Axis. Frontiers in Immunology, 11, Article No. 1975. [Google Scholar] [CrossRef] [PubMed]